ENO1 and neoplasm: Functional assays with the TLR4 inhibitor TAK-242 demonstrated that TLR4 blockade reversed rhENO1-induced tumor proliferation, migration, and invasion (Fig. 4I–L), confirming TLR4’s role in ENO1-driven malignancy.